Lung Cancer
Conditions
Keywords
stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer, recurrent non-small cell lung cancer
Brief summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving pemetrexed disodium may help doctors learn more about the effects of pemetrexed disodium on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This laboratory study is looking at blood samples from patients with stage III or stage IV non-small cell lung cancer enrolled in clinical trial MCCRC-RC0524 to determine the effect of pemetrexed disodium on cells.
Detailed description
OBJECTIVES: Primary * Assess the intracellular level of pemetrexed disodium (PD) polyglutamates as a measure of activity of PD transport and activation enzymes in patients with stage III or IV non-small cell lung cancer enrolled in clinical trial MCCRC-RC0524. Secondary * Assess polymorphisms and gene expression of PD target genes and genes encoding enzymes involved in the transport, activation, and inactivation of PD in these patients. * Correlate haplotype-tagged single-nucleotide polymorphisms (htSNPs) and gene expression levels with intracellular levels of PD polyglutamates * Correlate htSNPs and gene expression levels with toxicity and efficacy of PD. OUTLINE: Blood is drawn prior to and 24 hours after day 1 of course 1 of pemetrexed disodium. DNA is extracted and genotyped for known polymorphisms in genes involved in the transport, activation, inactivation, and mechanism of action or resistance of pemetrexed disodium, including reduced folate carrier-1, multiresistance proteins (particularly MRP5), folate receptor, folypolyglutamate synthase, methylenetetrahydrofolate reductase (MTHFR), methionine synthase, methylthioadenosine phosphorylase, thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Plasma and red blood cells are also processed for an intracellular polyglutamate assay for pemetrexed disodium by a high-performance liquid chromatography-based method. PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Interventions
GENETICgene expression analysis
GENETICpolymorphism analysis
GENETICprotein expression analysis
Sponsors
National Cancer Institute (NCI)
Mayo Clinic
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Enrolled in clinical trial MCCRC-RC0524 * Willing to provide blood samples PATIENT CHARACTERISTICS: * No investigator site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study * Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted * Not employed by Eli Lilly (i.e., employee, temporary contract worker, or designee responsible for conducting the study) * Immediate family of Eli Lilly employees allowed, but may not participate at an Eli Lilly facility PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Activity of pemetrexed disodium (PD) transport and activation enzymes as measured by intracellular content of PD polyglutamates | — |
Secondary
| Measure | Time frame |
|---|---|
| Polymorphisms and gene expression of PD target genes (RFC-1, MRP, folate receptor, FPGS, methylenetetrahydrofolate reductase, methionine synthase, methylthioadenosine phosphorylase, TS, DHFR, GARFT) | — |
| Polymorphisms and gene expression of genes encoding enzymes involved in the transport, activation, and inactivation of PD | — |
| Correlation of haplotype-tagged single-nucleotide polymorphisms (htSNPs) and gene expression levels with intracellular levels of PD polyglutamates | — |
| Correlation of htSNPs and gene expression levels with toxicity and efficacy of PD | — |
Countries
United States
Outcome results
None listed